Prestige Consumer Healthcare (PBH) Income from Non-Controlling Interests (2020)
Prestige Consumer Healthcare's (PBH) quarterly Income from Non-Controlling Interests came in at $1.1 million in Q4 2020, up 6.9% quarter-over-quarter from $985000.0 in Q3 2020.
Prestige Consumer Healthcare (PBH) Income from Non-Controlling Interests (2020) Analysis & Trends
Prestige Consumer Healthcare's Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at $1.1 million for Q4 2020.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to $1.1 million in Q4 2020; TTM through Dec 2020 was -$2.5 million, a N/A change from a year earlier, with the FY2020 full-year figure at -$4.9 million, changed N/A from the prior year.
- Income from Non-Controlling Interests grew to $1.1 million in Q4 2020 per PBH's latest filing, from $985000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.1 million in Q4 2020 and bottomed at -$4.9 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.01 Bn | 20.86 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.02 Bn | 22.02 Bn | - | - |
| 7 | Viatris | 20.40 Bn | 18.59 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.74 Bn | 12.31 Bn | 785.00 Mn | - |
| 10 | Prestige Consumer Healthcare | 2.42 Bn | 2.36 Bn | 157.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1.05 Mn |
| Sep 30, 2020 | 985,000.00 |
| Jun 30, 2020 | 309,000.00 |
| Mar 31, 2020 | -4.86 Mn |